26 November 2014
How To Build Real Patient-Centered Pharmaceutical Companies
Rob Wright, Life Science Leader
With such a focus these days on buzzwords such as "patient-centric," "patient-centered," and "patient-centricity," some people are predicting “patient engagement” to be the next big movement in our industry, much as blockbuster drugs were a decade or more ago. But while improving patient engagement sounds fairly straightforward for those who directly interact with patients (e.g., doctors, nurses, nurse practitioners, and physicians assistants), for the biopharmaceutical industry, successfully executing this concept has been — and continues to be — much more challenging.
25 November 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
Randi Hernandez, BioPharm International
Global spending on medicines will skyrocket by as much as 30% over the next five years, increasing to $1.3 trillion in 2018, according to a new forecast from the IMS Institute for Healthcare Informatics. The higher levels of growth in drug spending will be due to the waning impact of patent expiries, increased access to medicine worldwide, and the introduction of new specialty medications.
25 November 2014
Breakthrough Therapy Program Exceeds FDA’s Expectations
Jill Wechsler, Pharma Executive
The two-year-old initiative to accelerate the development and approval of highly effective drugs and biologics has enabled a number of important new medicines to reach patients sooner, according to Janet Woodcock, director of the Center for Drug Evaluation and Research (CDER). Twelve breakthrough drugs have been approved over the past two years, for several critical conditions as well as cancer, and dozens more are in the pipeline.
25 November 2014
2015 Pipeline Report: Burning Bright
Josh Baxt, PHARMACEUTICAL EXECUTIVE
Tracking new therapies as they wind their way through development, regulatory approval, and payer acceptance can be like waiting for paint to dry and then repainting in a different color. It's a slow process and far from linear.
25 November 2014
FDA posing options for faster antibacterial development
BioCenture
FDA's Anti-Infective Drugs Advisory Committee (AIDAC) is being asked to weigh in on the feasibility of clinical trial designs to streamline the development of antibacterial drugs in the face of "more commonplace bacterial resistance."
24 November 2014
Health Care M&A Leads Global Deal Surge
Linda A. Johnson and Steve Rothwell, ABC News
In a big year for deal making, the health care industry is a standout.
24 November 2014
Powerful method to speed cancer drug discovery unveiled -
Science Daily
Research data published in the journal Cell Reports describe a new method that could hasten the discovery of new cancer therapeutics by identifying protein-protein interactions that could be targeted by medicines, Science Daily reported.
24 November 2014
Beware sketchy biotechs with big plans for Ebola, SEC says
Damian Garde, Feirce Biotech
The SEC has suspended the trading of a few microcap companies touting unverified Ebola treatments and tests, warning investors of penny stock peddlers looking to cash in on the West African outbreak that has killed thousands.
24 November 2014
Smartphone apps to assess mental health based on everyday behavior proliferating
Varun Saxena, Feirce Medical Devices
Diagnostic smartphone apps are proliferating. No, these apps don't somehow turn the phone into a needle for drawing blood; instead they monitor stuff we take for granted, like talking or the movement of our eyes.
21 November 2014
World projected to spend $1T on drugs in 2018
Deborah Weinstein, Medical Marketing&Media
The top-line news from the IMS Institute for Healthcare Informatics is that the world is on track to spend $1.3 trillion on medications by 2018, or 30% more than it did in 2013.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.